newsfilter
← Latest News
GlobeNewswire·

RenovoRx to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026

  • RenovoRx, Inc. (NASDAQ: RNXT) will release third quarter 2026 financial results & business highlights after market close on Thursday, November 5, 2026.
  • The company will host a conference call & webcast at 4:30 p.m. ET to discuss commercial execution, revenue growth drivers, & cash generation.
  • Management will provide updates on clinical progress for the Trans-Arterial Micro-Perfusion (TAMP™) platform to support greater physician adoption & expansion into additional solid tumor indications.
  • RenovoRx generated approximately $1.1 million in RenovoCath sales during 2025 & achieved record quarterly revenue of $909,000 in the second quarter of 2026.
  • The company is expanding orders from medical institutions, including high-volume National Cancer Institute-designated centers.
  • The Phase III TIGeR-PaC trial evaluating the intra-arterial gemcitabine candidate (IAG) achieved full enrollment in August 2026, with trial completion expected in the first half of 2027 & topline data readout expected in the second half of 2027.
  • IAG utilizes the FDA-cleared RenovoCath device & has received Orphan Drug Designation for pancreatic cancer & bile duct cancer, granting seven years of market exclusivity upon approval.
  • RenovoCath is a patented, FDA-cleared local drug-delivery device designed to minimize therapy toxicities versus systemic intravenous treatment.
  • The IAG combination product candidate remains under investigation & has not been approved for commercial sale.
  • Investor & media contact details are provided for further inquiries regarding the upcoming earnings release & conference call.